ClinicalTrials.gg
Active, not recruitingNCT07535775Updated Jun 26, 2026

Evaluate Safety, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of BCD-261 After Single Subcutaneous Injection in Healthy Chinese Volunteers

A Phase 1 interventional study of BCD-261 in Healthy Adult Participants, sponsored by SPH-BIOCAD (HK) Limited. Active, not recruiting at 2 sites in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-26.

Sponsored by SPH-BIOCAD (HK) Limited · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

The goal of this study is to evaluate the Safety, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of BCD-261 after Single Subcutaneous Injection in Healthy Chinese Volunteers

02

Conditions studied

  • Healthy Adult Participants
03

In context

Lead sponsor

SPH-BIOCAD (HK) Limited is the lead sponsor of 3 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed to participate in the study.
  2. Male and female chinese subjects aged 18 to 45 years inclusively at the time of signing the ICF.
  3. The ability of the subject to follow the Protocol procedures, in the Investigator's opinion.
  4. A diagnosis of "healthy", established according to standard clinical, laboratory, and instrumental methods of examination carried out at screening, according to the assessment of the Investigator, as well as historical data (respiratory system, cardiovascular system, nervous systems, gastrointestinal tract system, urinary systems and etc.).
  5. Systolic blood pressure (SBP) ranging 90 to 139 mmHg, diastolic (DBP) ranging 50 to 89 mmHg, pulse ranging 50 to 100 bpm at screening.
  6. Willingness of the subjects and their female partners of to use reliable methods from the moment of signing the ICF, throughout the whole study participation. This requirement does not apply to participants who have undergone surgical sterilization.
  7. Willingness of subjects with to refrain from donating sperm/ oocytes, starting from the moment of signing the ICF, throughout the whole study participation. Females of childbearing potential must have a negative serum pregnancy test, be non-lactating, and have no plans to become pregnant during the study.
  8. Willingness to refrain from participating in any other clinical trials, starting from the moment of signing the ICF and throughout the whole study participation.
  9. Willingness to refrain from vaccination with any vaccines during the period from the moment of signing the ICF throughout the whole study participation.

    -

Exclusion criteria

Exclusion Criteria:

  • 1. Any medical or social condition that, in the opinion of the Investigator, prevents participation in this study.

    2. Any confirmed or suspected or immunodeficiency condition. 3. History of malignant disease. 4. Any acute infectious and non-infectious diseases, including the period of convalescence, within 4 weeks from the moment of clinical recovery to signing the ICF, as well as during screening.

    5. Diagnosis of infectious mononucleosis (documented or reported by the subject) within 2 months before signing the ICF and during screening.

    6. Vaccination with within 8 weeks and with any other vaccines within 4 weeks prior to signing the ICF and during screening.

    7. A history of allergies and signs of other significant adverse reactions after the administration of any medicinal products.

    8. to the components of BCD-261. 9. (BMI) outside the normal range (18.0 to 28.0 kg/m2). 10. Results of standard laboratory and instrumental tests (, chest radiogrpahs) outside the normal ranges adopted at the study site and considered by the investigator.

    11. Positive results of screening tests for (anti-HIV antibodies and HIV antigen), (HBsAg, total anti-HBc, anti-HBs ) and C (anti- antibodies) and/or syphilis antibody.

    12. History of tuberculosis or current diagnosis of tuberculosis, or latent tuberculosis (positive IGRA).

    13. Repeated positive urine drug test, repeated positive alcohol test at screening.

    14. Difficulty with blood collection or intolerance to venipuncture (e.g., history of needle or blood phobia, skin disease at the puncture site).

    15. Administration and use of the prohibited drugs. 16. Smoking of more than 10 cigarettes a day. 17. Consumption of more than 10 units of alcohol per week (1 unit of alcohol is equivalent to ½ L of beer, 200 mL of wine or 20 mL of spirits) or a history of alcoholism, drug addiction or drug abuse.

    18. Surgical interventions performed less than within 90 days before the signing of the ICF or planned surgery during the study period.

    19. Donation of 450 mL or more of blood or plasma within 60 days prior to signing the ICF.

    20. Participation in any clinical study of medicinal products and devices within 90 days before signing the ICF or previous participation in the current study with the exception of subjects who withdrew before the administration of the product

Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
48 participants (estimated)

Study arms

  • Experimental
    BCD-261 Dose Regimen A

    BCD-261 Dose Regimen A administered by subcutaneous injection

    Drug: BCD-261

  • Experimental
    BCD-261 Dose Regimen B

    BCD-261 Dose Regimen B administered by subcutaneous injection

    Drug: BCD-261

  • Experimental
    BCD-261 Dose Regimen C

    BCD-261 Dose Regimen C administered by subcutaneous injection

    Drug: BCD-261

Interventions

  • DrugBCD-261

    Anti-TL1A human monoclonal antibody. Solution for Subcutaneous Injection.

06

What researchers measure

Primary outcomes

  1. proportion of subjects with serious adverse events

    Time frame: 309days

  2. proportion of subjects with adverse events

    Time frame: 309days

  3. proportion of subjects with CTCAE grade 3 or higher adverse events

    Time frame: 309days

  4. proportion of subjects who prematurely withdrew from the study due to adverse events.

    Time frame: 309days

Other outcomes

  1. Cmax

    Maximum concentration

    Time frame: 309days

  2. Tmax

    Time of maximum observed concentration

    Time frame: 309days

  3. T1/2

    Elimination half-life period

    Time frame: 309days

  4. Kel

    Elimination rate constant

    Time frame: 309days

  5. Cmin

    Minimum observed concentration

    Time frame: 309days

07

Study locations

2 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2026 (actual). Primary completion is estimated for Oct 2026, 4 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 31, 2026
First posted
Apr 17, 2026
StartActual
May 11, 2026
Primary completionEst.
Oct 10, 2026
CompletionEst.
Mar 20, 2027
Last update
Jun 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 26, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07535775
Lead sponsor
SPH-BIOCAD (HK) Limited
Responsible party
Sponsor
First posted
Apr 17, 2026
Start date
May 11, 2026
Primary completion
Oct 10, 2026 (estimated)
Completion
Mar 20, 2027 (estimated)
Last update
Jun 26, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion